
    
      This is a single center phase I clinical trial assessing the safety of combination therapy of
      TSEBT and pembrolizumab for treatment of Stage IB-IV relapsed/refractory MF and SS.

      Primary Endpoint:

      â€¢ Primary endpoint will be maximum tolerated dose (MTD).

      Secondary Endpoints:

        -  Efficacy of the combination of TSEBT with pembrolizumab therapy is measured.

        -  CTCAE v4.0 toxicity beyond the 30 day period following the second therapy in the
           combination protocol treatment and up to 30 days following last dose of pembrolizumab.

        -  Skindex-29 patient-reported HRQOL survey.

      Sample Size and Accrual: 18 patients will be enrolled.

      Statistical Analysis: Time to event will be estimated using the Kaplan-Meier approach along
      with the 95% confidence interval.
    
  